ArticleBMC pediatrics2026
Neurological manifestations in Nigerian children with sickle cell disease: a single-center retrospective study.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSickle cell disease (SCD) is a hereditary hemoglobinopathy that poses a significant public health problem in Nigeria, associated with significant morbidity and mortality among affected children. Neurological manifestations contribute substantially to disability and adverse outcomes, however, comprehensive data on their burden and determinants in pediatric SCD patients remain limited.
methodsThis single-center retrospective study examined children under 15 years of age with confirmed SCD managed at Olabisi Onabanjo University Teaching Hospital (OOUTH) between March 2022 and February 2025. A structured proforma was used to extract demographic data, clinical history, neurological manifestations, associated factors, and outcomes. The neurological manifestations assessed included seizure, stroke, paralysis, headache, visual disturbance, and silent cerebral infarct. Laboratory and imaging data, where available, were used to support the diagnoses. Data were analyzed using descriptive and bivariate statistical methods.
resultsAmong the 133 children with SCD, 28 (21.1%) had documented neurological manifestations. Seizures were the most frequent (12.8%), followed by headaches (9.8%), paralysis (9.0%), and stroke (6.8%). Most neurological events occurred between 5 and 10 years of age, with a mean onset of 7.2 ± 3.8 years. Neurological manifestations were significantly associated with age at presentation (p = 0.032), higher frequency of crises (p = 0.02), and prior history of neurological manifestations (p < 0.001). No statistically significant associations were observed between neurological manifestations and sex (p = 0.232), anemia (p = 0.6), or infections (p = 0.812). Neurological manifestations were associated with increased mortality, residual deficits, and longer hospital stay. Neurological manifestations were present in half (n = 4) of all recorded deaths, with an overall mortality of 6% in the patients studied. Among survivors, approximately one-third had residual neurological deficits.
conclusionNeurological manifestations in children with SCD are relatively common and are associated with adverse outcomes, including disability and prolonged hospitalization. These findings underscore the urgent need for improved early detection and context-appropriate preventive and management strategies to reduce this burden in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.